4D Molecular Therapeutics (FDMT) said Friday that it will focus on two product candidates: 4D-150 for wet AMD and DME, and 4D-710 for cystic fibrosis.
The company said the two candidates have the strongest clinical proof of concept within its product pipeline.
4D said it is on track to begin late-stage trials for wet AMD in Q1 and Q3 respectively, with primary endpoint 52-week topline data expected in H2 2027.
Shares of the biotech firm were up 5.7% in recent premarket activity.
Price: 6.16, Change: +0.32, Percent Change: +5.65
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.